BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alecensa (Alectinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Alecensa (Alectinib)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04302025-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT04302025)
DESCRIPTION:Alecensa (Alectinib)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of Multiple Therapies in Biomarker-selected Participants Wit
 h Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated p
 rimary completion: 30 November 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/alectinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05713006-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT05713006)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Alectinib Pharmacokinetic in Patients With NSCLC\nEstimated primar
 y completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/alectinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05713006
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322890-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT04322890)
DESCRIPTION:Alecensa (Alectinib)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Treatment Strategies and Survival Outcome for Non-small Cell Lung Ca
 ncer With Oncogenic Mutation\nEstimated primary completion: 24 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04322890
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Alecensa (Alectinib): Phase 3 readout est. (NCT05170204)
DESCRIPTION:Alecensa (Alectinib)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Therapies in 
 Cohorts of Participants With Locally Advanced\, Unresectable\, Stage III N
 on-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 19 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0517020
 4
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alecensa (Alectinib): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Alecensa (Alectinib)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Multiple Targeted T
 herapies as Treatments for Participants With Non-Small Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT02925234)
DESCRIPTION:Alecensa (Alectinib)\, phase 2.\nStudy: The Drug Rediscovery Pr
 otocol (DRUP Trial)\nEstimated primary completion: September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT06692491)
DESCRIPTION:Alecensa (Alectinib)\, phase 2.\nStudy: Study of Precision Trea
 tment for Rare Tumours in China Guided by PDO and NGS\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/alectinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06692491
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987644-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT05987644)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Can
 cer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases a
 nd ALK rEarrangements\nEstimated primary completion: 28 February 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05987644
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Alecensa (Alectinib): Phase 3 readout est. (NCT03768063)
DESCRIPTION:Alecensa (Alectinib)\, phase 3.\nStudy: A Study in Patients Pre
 viously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored 
 Atezolizumab Study\nEstimated primary completion: 5 July 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06709274-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Alecensa (Alectinib): Phase na readout est. (NCT06709274)
DESCRIPTION:Alecensa (Alectinib)\, phase na\, Non-Small Cell Lung Cancer.\n
 Study: Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC\
 nEstimated primary completion: January 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/alectinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06709274
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03202940-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT03202940)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase IB/II Study of Alectinib Combined With Cobimetinib in Adva
 nced ALK-Rearranged (ALK+) NSCLC\nEstimated primary completion: 1 January 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03202940
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560410-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT07560410)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2.\nStudy: Treatment of Truncate
 d ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecen
 sa)\nEstimated primary completion: 15 January 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07560410
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT04341181)
DESCRIPTION:Alecensa (Alectinib)\, phase 2.\nStudy: ProTarget - A Danish Na
 tionwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Prof
 iling\nEstimated primary completion: 30 April 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05770037-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Alecensa (Alectinib): Phase 2/3 readout est. (NCT05770037)
DESCRIPTION:Alecensa (Alectinib)\, phase 2/3.\nStudy: DETERMINE Trial Treat
 ment Arm 01: Alectinib in Adult\, Paediatric and Teenage/Young Adult Patie
 nts With ALK Positive Cancers\nEstimated primary completion: October 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05770037
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Alecensa (Alectinib): Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Alecensa (Alectinib)\, phase 2/3.\nStudy: DETERMINE (Determinin
 g Extended Therapeutic Indications for Existing Drugs in Rare Molecularly 
 Defined Indications Using a National Evaluation Platform Trial) - Master S
 creening Protocol\nEstimated primary completion: October 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573696-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20300208
DTEND;VALUE=DATE:20300209
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT07573696)
DESCRIPTION:Alecensa (Alectinib)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant
  Alectinib and Chemotherapy\nEstimated primary completion: 8 February 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07573696
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001384-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20310808
DTEND;VALUE=DATE:20310809
SUMMARY:Alecensa (Alectinib): Phase 1 readout est. (NCT07001384)
DESCRIPTION:Alecensa (Alectinib)\, phase 1.\nStudy: A Study of Alectinib an
 d Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic 
 Large Cell Lymphoma (ALK+ALCL)\nEstimated primary completion: 8 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07001384
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT05159245)
DESCRIPTION:Alecensa (Alectinib)\, phase 2.\nStudy: The Finnish National St
 udy to Facilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated 
 primary completion: 25 November 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/alectinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04774718-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20320228
DTEND;VALUE=DATE:20320229
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT04774718)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2.\nStudy: A Study Evaluating th
 e Safety\, Pharmacokinetics\, and Efficacy of Alectinib in Pediatric Parti
 cipants With ALK Fusion-Positive Solid or CNS Tumors\nEstimated primary co
 mpletion: 28 February 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/alectinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04774718
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04589845-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20320925
DTEND;VALUE=DATE:20320926
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT04589845)
DESCRIPTION:Alecensa (Alectinib)\, phase 2.\nStudy: Tumor-agnostic Precisio
 n Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platfo
 rm Study\nEstimated primary completion: 25 September 2032. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04589845
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916389-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20341130
DTEND;VALUE=DATE:20341201
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT07916389)
DESCRIPTION:Alecensa (Alectinib)\, phase 2.\nStudy: Molecularly Stratified 
 Trial for Newly Diagnosed Infant-Type Hemispheric Glioma\nEstimated primar
 y completion: November 2034. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/alectinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07916389
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05725200-2016@assetmemo.bio
DTSTAMP:20261121T004518Z
DTSTART;VALUE=DATE:20381231
DTEND;VALUE=DATE:20390101
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT05725200)
DESCRIPTION:Alecensa (Alectinib)\, phase 2.\nStudy: Study to Investigate Ou
 tcome of Individualized Treatment in Patients With Metastatic Colorectal C
 ancer\nEstimated primary completion: 31 December 2038. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05725200
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
